Nodular lymphocyte predominant Hodgkin lymphoma: Advances in disease biology, risk stratification and treatmentRead More
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyRead More
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapiesRead More
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II TrialRead More
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyRead More
Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapseRead More
A Randomized Phase 3 Trial of Zanubrutinib versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: THE ASPEN STUDYRead More
